Running Projects
Our group is currently conducting several interdisciplinary projects focusing on precision prevention, early detection, and clinical research methodology.
These projects integrate genomics, microbiome, AI/LLMs, and health policy modeling, aiming to transform cancer screening and prevention strategies in China and globally.
Risk-adapted Screening for Colorectal Cancer
We conducted the first large-scale randomized controlled trial (RCT) in China to compare the feasibility, participation, and diagnostic yield of risk-adapted colorectal cancer (CRC) screening with colonoscopy and fecal immunochemical test (FIT) — the TARGET-C trial. Approximately 20,000 participants aged 50–74 years were enrolled. The trial has built a comprehensive database and biobank, forming a robust platform for future CRC prevention and early detection research.
Polygenic Risk Score for Colorectal Cancer
We are developing and validating polygenic risk score (PRS) models by integrating data from the China Kadoorie Biobank and multiple population-based screening cohorts. This project aims to provide precise estimation of individual absolute risk and enable large-scale, genetics-informed risk-adapted screening.
Gut Microbiome and CRC
We investigate gut microbial signatures and host–microbiome interactions influencing CRC development. Integrating metagenomic, lifestyle, and genetic data, we build metagenomic risk scores (MRS) for early detection, and study how environmental and genetic factors shape the microbiome and carcinogenesis.
AI and Large Language Models for Cancer Prevention
Developing AI- and LLM-driven platforms for the end-to-end management of cancer screening — from intelligent risk assessment to personalized follow-up. A pilot study, INTEL-PATH CRC, is evaluating the feasibility of AI-assisted screening strategies in real-world settings.
Health Economics & Policy Simulation
Applying microsimulation and decision-analytic models to evaluate the long-term effectiveness and cost-effectiveness of both primary (risk factor control) and secondary (screening-based) prevention strategies for CRC. These analyses guide evidence-based policy and optimize prevention resources.
Lifestyle and Cancer Comorbidity
Investigating how lifestyle factors (diet, physical activity, smoking, alcohol, metabolic status) influence comorbidity patterns between cancer and chronic diseases. The project identifies modifiable risks and promotes integrated prevention and survivorship care.
Novel plasma proteomics-based colorectal cancer screening biomarker
Using mass spectrometry–based plasma proteomics to discover and validate circulating protein biomarkers for early colorectal cancer detection. By integrating proteomic, genetic, and clinical data, this project enhances non-invasive colorectal cancer screening and early-detection tools.
CREDIT: Clinical Research Intelligent Design & Evaluation Tool
CREDIT is an AI-empowered platform for clinical research design, evaluation, and quality management. Leveraging large language models and knowledge-graph reasoning, it assesses study rigor and provides automated feedback aligned with international standards (CONSORT, STROBE, PRISMA).
Integrated Screening for Upper Gastrointestinal and Colorectal Cancer
Developing a combined screening strategy for upper GI and colorectal cancers in high-altitude Tibetan populations, integrating endoscopic and non-invasive methods to improve efficiency and explore shared etiological pathways.
Global Lifetime Risk and Preventable Burden of Colorectal Cancer
Quantifying the global lifetime risk and preventable incidence of colorectal cancer attributable to modifiable risk factors across countries worldwide. This study will use comparative modeling and population-attributable risk estimation to assess regional variations and identify the potential impact of targeted prevention strategies, providing evidence to guide international cancer prevention and screening policies.
Cervical cancer screening and triaging strategy
For women at high risk of cervical cancer, this study will evaluate the effectiveness of E6/E7 mRNA testing, DNA methylation markers, dual-stain cytology (p16/Ki-67), and conventional cytology in triaging hrHPV-positive cases. We aim to compare their diagnostic performance and explore the optimal triaging strategy that achieves a balance between accuracy, feasibility, and cost-effectiveness.